Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015  Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and ... results from a Category 3 human abuse ... extended-release, oral oxycodone product candidate in late-stage ... severe enough to require daily, around-the-clock opioid ...
(Date:6/29/2015)... Mordor Intelligence presents their Global Pharmaceutical Packaging Market ... Metal) - ByType of Packaging (Ampules, Blister Packs, Bottles, Canisters, ... By Geographical Region ( North America , ... Latin America , Middle East ... Industry Value Chain Analysis, Porter,s 5 Force Analysis, Drivers, Restraints, ...
(Date:6/29/2015)... PARK, Calif. , June 29, 2015  Nevro ... company that is providing innovative evidence-based solutions for the ... Earnhardt , President and Chief Executive Officer of Intersect ... its Board of Directors, effective June 28, 2015. ... Earnhardt has successfully led Intersect ENT, a company ...
Breaking Medicine Technology:Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3Nevro Appoints Lisa Earnhardt to its Board of Directors 2
... DIEGO, April 19, 2011 Sangart, Inc., today announced that ... funding from existing investors, led by Leucadia National Corporation. The ... company since its inception in 1998 to more than $230 ... could provide up to an additional $50 million in future ...
... Ohio woman suffered bone deterioration and broken bones because ... reflux drug Nexium,  The Gibson Law Firm alleges ... Filed in the U.S. District Court in ... Ohio, suffered serious bone deterioration after taking Nexium ...
Cached Medicine Technology:Sangart Announces Closing of $50 Million Series G Financing 2AstraZeneca Sued Over Alleged Nexium Injuries, According to The Gibson Law Firm 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... alleging heart attack and stroke incidents are linked to testosterone replacement therapy announce ... Management Conference is scheduled for July 9, 2015, according to court documents.* The ...
(Date:6/30/2015)... ... June 30, 2015 , ... Nuretix Research, creators ... Knockout Zone Miami (KO Zone), a state-of-the-art training facility owned by ... Diego de Vera. The partnership will provide KO Zone clients and athletes with ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Amerec, a division ... course offered through AEC Daily is now approved by the Interior Design Continuing ... through AEC Daily, provides an overview and explanation of what sauna, steam, and far-infrared ...
(Date:6/30/2015)... ... 30, 2015 , ... New Xarelto lawsuit claims proposed for ... new forms, according to attorneys handling Xarelto lawsuits included in the ... “provide guidance” for plaintiffs’ attorneys in filing new claims, according to court documents. ...
(Date:6/30/2015)... ... June 30, 2015 , ... AvePoint, the ... availability of three new apps – AvePoint Watermark, AvePoint MyWorld, ... addition of these apps, workers can better streamline everyday business operations and take advantage ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3Health News:Amerec’s Steam and Sauna Continuing Education Course Now Approved for Interior Design Credit 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4
... doesn,t find any particular class of these medications more ... new study finds no particular antidepressant is more likely ... medication will kill themselves or try to commit suicide. ... antidepressants, especially selective serotonin reuptake inhibitors such as Prozac ...
... ... lab industry in the form of new business, but downward pressure on Medicare reimbursement rates ... Slone Partners teleconference on the new law April 21. , ... Miami, FL (PRWEB) May 4, 2010 -- The health care ...
... ... of the Erase-O-Matic, a compact degausser designed to demagnetize digital video and computer tape ... , ... CA (PRWEB) May 4, 2010 -- Data Devices International , a leader in ...
... ... (AWWA) is urging students and job seekers to explore the water sector to discover careers ... , ... 4, 2010 -- As Drinking Water Week continues, the American Water Works Association ...
... COLUMBIA A study of emergency department (ED) activity ... role public fear can play in unnecessarily straining medical ... health emergencies, according to the authors. When ... during a pandemic, the quality and timeliness of medical ...
... increased misuse, serious injuries, and overdose deaths have ... create a new guideline for opioid use with ... CMAJ ( Canadian Medical Association Journal ) ... use in Canada has increased significantly, with a ...
Cached Medicine News:Health News:No One Antidepressant Raises Suicide Risk More Than Others 2Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 2Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 3Health News:Data Devices International Secures Exclusive Worldwide Distribution of the Erase-O-Matic Digital Video and Computer Tape Eraser 2Health News:During Drinking Water Week 2010, Water Sector Urges Students, Job Seekers to Work for Water 2Health News:Fear of pandemic influenza clogs EDs even when disease is not present 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: